WO2014007774A1 - Formulations solubles dans l'eau comprenant un principe actif dérivé de pipéridine - Google Patents

Formulations solubles dans l'eau comprenant un principe actif dérivé de pipéridine Download PDF

Info

Publication number
WO2014007774A1
WO2014007774A1 PCT/TR2013/000202 TR2013000202W WO2014007774A1 WO 2014007774 A1 WO2014007774 A1 WO 2014007774A1 TR 2013000202 W TR2013000202 W TR 2013000202W WO 2014007774 A1 WO2014007774 A1 WO 2014007774A1
Authority
WO
WIPO (PCT)
Prior art keywords
water soluble
formulations
group
agent
formulations according
Prior art date
Application number
PCT/TR2013/000202
Other languages
English (en)
Inventor
Mahmut Bilgic
Original Assignee
Mahmut Bilgic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mahmut Bilgic filed Critical Mahmut Bilgic
Publication of WO2014007774A1 publication Critical patent/WO2014007774A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Definitions

  • the present invention is related to water soluble formulations comprising (+/-) 2,3-Dihydro-5,6- dimethoxy-2-[( l-(phenylmethyl)-4-piperidinyl]methyl]-l H-inden-l-one that shall be used in the symptomatic treatment of types of Alzheimer's Disease varying from mild to moderate.
  • Donepezil (formula I), which has the chemical name +/-) 2,3-Dihydro-5,6-dimethoxy-2-[(l - (phenylmethyI)-4-piperidinyI]methyI]-l H inden-l-one, is a cholinesterase inhibitor and first disclosed in the patent application US4895481.
  • Donepezil is marketed in film tablet and orodispersible tablet forms. These formulations are indicated for treatment of Alzheimer's disease. General symptoms of Alzheimer's disease can be listed as memory loss, mental confusion and increase in behavioral changes.
  • the active agent is a crystalline powder which dissolves well in water.
  • a significant problem for formulations comprising donepezil is low stability of the active agent in spite of its high water solubility.
  • the stabilizing agents in said patent application are agents such as edetate, sulfite, butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT).
  • BHA and BHT are synthetic antioxidants which are frequently used in cosmetics, food and pharmaceutical sector.
  • BHA and BHT are synthetic antioxidants which are frequently used in cosmetics, food and pharmaceutical sector.
  • BHA and BHT are synthetic antioxidants which are frequently used in cosmetics, food and pharmaceutical sector.
  • these compounds used to provide stability cause serious health problems in users due to their oxidative nature. For instance, use of these two agents induces allergic reaction on skin 1 .
  • the studies conducted on animals have proved that use of high doses of BHT causes impairments on liver, kidney and lung functions 2 .
  • EP 1086706 explains stable formulations comprising an organic acid such as tosylic, mesylic, benzoic, salicylic acid in addition to an anti-dementia agent such as donepezil.
  • an organic acid such as tosylic, mesylic, benzoic, salicylic acid
  • sensitivity of the active agent especially to light is prevented by use of the given acids in formulations.
  • stability of the active agent to moisture and storage conditions should also be provided.
  • the solution provided in scope of the patent is not sufficient.
  • the inventors have managed to prepare stabile donepezil formulations without need to use any stabilizing agent.
  • the formulations of the present invention do not have any negative effect on human health as they do not comprise a stabilizing agent.
  • formulations of the present invention can preserve their stability for long periods of time under storage conditions.
  • the formulations of the present invention have been prepared in water soluble form since they appeal to a wide patient profile and provide high bioavailability.
  • Water soluble forms are more advantageous compared to conventional forms due to their fast dispersion. These formulations release the active agent/agent into aqueous liquid fast and simultaneously. Time spent between adding the formulations into water and its dispersion and intake of the solution is relatively shorter and a possible stability problem that can appear in the formulations is minimized this way.
  • pharmaceutical formulations in water soluble forms are advantageous as they provide ease of use for the ones who cannot swallow solid pharmaceutical forms.
  • a characteristic feature of the water soluble donepezil formulations of the present invention is that formulations do not comprise a stabilizing agent.
  • stabilizing agent used herein refers to compounds such as antioxidant edetate and sulfite group compounds, BHA and BHT, propyl gallate, ascorbyl palmitate, alpha tocopherol, ascorbic acid.
  • another feature of the water soluble donepezil formulations of the present invention is that said formulations do not comprise a compound selected from a group comprising antioxidant edetate and sulfite group compounds, BHA and BHT as the stabilizing agent.
  • Dextrins are a group of low-molecular-weight carbohydrate molecules basically produced by the - acidic hydrolysis of starch and used in very different areas for different purposes in the prior art. They can be used as binder, diluent and/or sweetener in pharmaceutical formulations. Primary dextrin compounds are maltodextrin, cyclodextrin or amylodextrin.
  • a dextrin group compound in the water soluble donepezil formulations of the present invention is advantageous since it provides a pleasant taste to the formulations. With this improved taste, there appears no need for use of high amounts of sweetener and/or flavoring agent in order to suppress the bitter taste of the active agent. By this means, both large sizes of dosage forms which would prevent swallowing and the increase of production costs are impeded.
  • a characteristic feature of water soluble donepezil formulations of the invention is that said formulations comprise;
  • a dextrin group excipient selected from a group comprising maltodextrin, cyclodextrin and/or amylodextrin and
  • water soluble formulations of the present invention comprise a dextrin group excipient selected from a group comprising maltodextrin, cyclodextrin and/or amylodextrin in the range of 1% and 15% by weight.
  • said formulations comprise a dextrin group excipient selected from a group comprising maltodextrin, cyclodextrin and/or amylodextrin in the range of 1 % and 10% by weight.
  • Another chkracteristic feature of the water soluble formulations of the present invention is that said formulations comprise a dextrin group excipient selected from a group comprising maltodextrin, cyclodextrin and/or amylodextrin in the range of 2% and 8% by weight.
  • the characteristic of the water soluble formulations of the present invention is that the dextrin group excipient is maltodextrin.
  • Donepezil used in water soluble formulations of the present invention can be in the form of donepezil or its pharmaceutically acceptable salts, hydrates, solvates, esters, enantiomers, diastereomers or combinations thereof.
  • the water soluble donepezil formulations of the present invention can comprise donepezil in the range of 1 and 50 mg, preferably in the range of 1 and 45 mg, more preferably in the range of 1 and 40 mg per unit dosage form.
  • the formulations can optionally be used in combination with another active agent.
  • the second active agent can be selected from antacid, antihistaminic, anticholinergic, antispasmodic, antiemetic, antibiotic, antipropulsive, antiallergic, antidiarrheal, antiobesity, antithrombotic, antifibrinolytic, antianemic, antihypertensive, antifungal, antipruritic, antipsoriatic,- antibiotic, antiseptic, antiacne, antibacterial, antimycotic, antiviral, antineoplastic ⁇ antiarrhythmic, antiadrenergic, antiepileptic, anti-parkinson, antiprotozoal, anthelmintic, anti-inflammatory, diuretic, laxative, sulphonamide, imidazole, corticosteroid, thiazolidinedione, biguanide, immunostimulant, immunosuppressant, myorelaxant, analgesic, psycholeptic, psychoanaleptic peripheral vasodilator, beta blocker, calcium
  • the water soluble formulations of the present invention can optionally be formulated in effervescent form.
  • excipients that can be comprised in the formulations are selected from a group comprising disintegrant, diluent, lubricant, glidant, binder, effervescent couple composed of at least one acidic agent and at least one basic agent, coloring agent, pH regulating agent, surfactant, stabilizing agent, sweetener and/or taste regulating agent, flavoring agent.
  • the disintegrant that can be used in the water soluble formulations of the present invention can be selected from a group comprising carboxymethyl cellulose, carboxymethyl cellulose calcium, carboxymethyl cellulose sodium, croscarmellose sodium, crospovidone, hydroxypropyl cellulose, microcrystalline cellulose, methylcellulose, chitosan, starch, sodium starch glycolafe.
  • the diluent that can be used in the water soluble formulations of the present invention can be selected from a group comprising can be selected from a group comprising calcium carbonate, dibasic calcium phosphate, tribasic calcium phosphate, calcium sulfate, microcrystalline cellulose, dextrose, fructose, lactitol, lactose, magnesium carbonate, magnesium oxide, maltitol, maltodextrin, maltose, mannitol, simethicone, sorbitol, starch, sodium chloride, sucrose, talc, xylitol.
  • the lubricant that can be used in the water soluble formulations of the present invention can be selected from a group comprising can be selected from a group comprising calcium stearate, magnesium stearate, polyethylene glycol, sodium benzoate, potassium benzoate, sodium lauryl sulfate, sodium stearyl fumarate, talc, stearic acid, zinc stearate.
  • the glidant that can be used in the water soluble formulations of the present invention can be selected from a group comprising tribasic calcium phosphate, colloidal silicone dioxide, magnesium silicate, magnesium trisilicate, talc.
  • the binder that can be used in the water soluble formulations of the present invention can be selected from a group comprising carboxymethyl cellulose sodium, ethyl cellulose, gelatine, hydroxyethyl cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hypromellose, magnesium aluminium silicate, maltodextrin, methylcellulose, povidone, starch.
  • the acidic agent comprised in the effervescent couple composed of at least one acidic agent and at least one basic agent that can be used in the water soluble formulations of the present invention can be selected from a group comprising organic acids such as malic acid, citric acid, tartaric acid, fumaric acid or pharmaceutically acceptable salts of these acids; and the basic agent can be selected from a group comprising agents such as sodium carbonate, potassium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate.
  • the pH regulating agent that can be used in the water soluble formulations of the present invention can be selected from citrate, phosphate, carbonate, tartrate, fumarate, acetate and amino acid salts.
  • the surfactant that can be used in the water soluble formulations of the present invention can be selected from sodium lauryl sulphate, polysorbate, polyoxyethylene, polyoxypropylene glycol and similar agents.
  • the stabilizing agent that can be used in the water soluble formulations of the present invention can be selected from a group comprising tocopherol, tetrasodium edetate, nicotinamide, cyclodextrin.
  • the sweetener and/or taste regulating agent that can be used in the water soluble formulations of the present invention can be selected from a group comprising acesulfame, aspartame, dextrose, fructose, maltitol, maltose, mannitol, saccharine, saccharine sodium, sodium cyclamate, sorbitol, sucralose, sucrose, xylitol, sodium chloride.
  • the flavoring agent that can be used in the water soluble formulations of the present invention can be selected from menthol, lemon, orange, vanilla, strawberry, ⁇ raspberry, caramel and simitar flavors.
  • the formulations of the present invention can be produced by any methods in the prior art such as dry blending methods, wet or dry granulation methods; however, the method preferred in the present invention is wet granulation method.
  • wet granulation method is applied by wet-granulating the dry mixture comprising the active agent and at least another excipient with the granulation solution comprising a pharmaceutically acceptable solvent and optionally at least another excipient and optionally adding at least another excipient into -the obtained granules and giving the granules their final shape.
  • the dextrin group excipient comprised in the water soluble formulations of the present and selected from a group comprising maltodextrin, cyclodextrin and/or amylodextrin can be comprised in any step of the production method. For instance, it can be added to the content of active agent mixture or granulation solution or some part of it can be comprised in the granulation solution while the rest is in the active agent mixture.
  • Example 1 Water soluble formulations comprising a dextrin group excipient
  • the mixture is wet-granulated with a pharmaceutically acceptable solvent
  • the flavoring agent is added to the sieved granules,
  • the obtained granules are formed in a desired shape.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des formulations solubles dans l'eau comprenant (+/-) du 2,3-Dihydro -5,6-diméthoxy-2-[(1-(phénylméthyl)-4-pipéridinyl]méthyl]-1 H-inden-1-one devant être utilisées dans le traitement des symptômes légers ou modérés de la démence de type maladie d'Alzheimer.
PCT/TR2013/000202 2012-07-02 2013-07-02 Formulations solubles dans l'eau comprenant un principe actif dérivé de pipéridine WO2014007774A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2012/07629 2012-07-02
TR201207629 2012-07-02

Publications (1)

Publication Number Publication Date
WO2014007774A1 true WO2014007774A1 (fr) 2014-01-09

Family

ID=49170841

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2013/000202 WO2014007774A1 (fr) 2012-07-02 2013-07-02 Formulations solubles dans l'eau comprenant un principe actif dérivé de pipéridine

Country Status (1)

Country Link
WO (1) WO2014007774A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107375945A (zh) * 2017-08-29 2017-11-24 沈阳药科大学 一种多奈哌齐环糊精包合物及含有此包合物的口服速溶膜剂

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4895481A (en) 1987-01-29 1990-01-23 Doris Engineering Non-rigid marine platform with surface wellheads
EP1086706A1 (fr) 1999-03-31 2001-03-28 Eisai Co., Ltd. Compositions stabilisees contenant des medicaments nootropes
EP2127651A1 (fr) 2007-01-19 2009-12-02 Eisai R&D Management Co., Ltd. Composition médicamenteuse stabilisée contenant du donépézil, procédé de fabrication et de stabilisation d'une telle composition
EP2213278A1 (fr) * 2009-01-28 2010-08-04 Labtec GmbH Préparation pharmaceutique ayant une stabilité améliorée d'agent actif
WO2012026904A1 (fr) * 2010-08-25 2012-03-01 Mahmut Bilgic Forme galénique unidose réalisée à partir d'une combinaison comprenant du donépézil et de l'extrait de ginkgo biloba

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4895481A (en) 1987-01-29 1990-01-23 Doris Engineering Non-rigid marine platform with surface wellheads
EP1086706A1 (fr) 1999-03-31 2001-03-28 Eisai Co., Ltd. Compositions stabilisees contenant des medicaments nootropes
EP2127651A1 (fr) 2007-01-19 2009-12-02 Eisai R&D Management Co., Ltd. Composition médicamenteuse stabilisée contenant du donépézil, procédé de fabrication et de stabilisation d'une telle composition
EP2213278A1 (fr) * 2009-01-28 2010-08-04 Labtec GmbH Préparation pharmaceutique ayant une stabilité améliorée d'agent actif
WO2012026904A1 (fr) * 2010-08-25 2012-03-01 Mahmut Bilgic Forme galénique unidose réalisée à partir d'une combinaison comprenant du donépézil et de l'extrait de ginkgo biloba

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Haz-Map: Occupational Exposure to Hazardous. Agents", NATIONAL LIBRARY OF MEDICINE, 2010, Retrieved from the Internet <URL:http://lhazmap.nlm.nih.gov.>
"L4RC Monographs on the Evaluation of Carcinogenic Risks to Humans", vol. 17, 1986, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER
STUDY ON ENHANCING THE ENDOCRINE DISRUPTER PRIORITY LIST WITH A FOCUS ON LOW PRODUCTION VOLUME CHEMICALS, REVISED REPORT TO DG ENVIRONMENT (HERSHOLM, DENMARK: DHI WATER AND ENVIRONMENT, 2007, Retrieved from the Internet <URL:http://ec.euro£a.eu/environmentlendocrine/documents/final_report 2007.pdf.>
UNEP AND OECD, 2,6-DI-TERT-BUTYL-P-CRESOL (BHT) SCREENING INFORMATION DATA SET: INITIAL ASSESSMENT REPORT, 2002, Retrieved from the Internet <URL:http://www.inchem.org/documents/sids/sids/128370.pdf>

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107375945A (zh) * 2017-08-29 2017-11-24 沈阳药科大学 一种多奈哌齐环糊精包合物及含有此包合物的口服速溶膜剂

Similar Documents

Publication Publication Date Title
EP2842549B1 (fr) Comprimé à désintégration orale et son procédé de production
ES2374200T3 (es) Formulación de liberación prolongada de paliperidona.
EP2528594B1 (fr) Formulations effervescentes contenant de la céphalosporine de deuxième génération
ES2688880T3 (es) Forma de dosificación de dispersión rápida que contiene levetiracetam
US20100016322A1 (en) Water Dispersible Pharmaceutical Formulation and Process for Preparing The Same
US10398694B2 (en) Multi-layered tablet containing drug unstable to light
KR20150001720A (ko) 1－(3－(2－(1－벤조티오펜－5－일)에톡시)프로필)아제티딘－3－올 또는 그 염을 함유하는 고형 의약 조성물
US20210145753A1 (en) Preparation containing 6,7-unsaturated-7-carbamoyl morphinan derivatives
ES2384333T3 (es) Composiciones farmacéuticas que tienen perfiles de disolución mejorados para fármacos poco solubles
BRPI0620790A2 (pt) formulação complexa que compreende cansilato de amlodipina e sinvastatina e método para a sua preparação
JP2010024181A (ja) 固形製剤及びその製造方法
US20090269393A1 (en) Chewable Bilayer Tablet Formulation
EP2243468A1 (fr) Compositions comprenant de la diméboline et se désintégrant oralement
US11185509B2 (en) Solid preparation having improved light stability
JP2015054851A (ja) 被覆経口固形製剤
WO2014007774A1 (fr) Formulations solubles dans l&#39;eau comprenant un principe actif dérivé de pipéridine
WO2014104989A1 (fr) Compositions pharmaceutiques comprenant de l&#39;aripiprazole
JP6108635B2 (ja) ロスバスタチン含有口腔内速崩壊錠
WO2012093971A2 (fr) Compositions effervescentes contenant de l&#39;amlodipine
WO2013109230A1 (fr) Compositions pharmaceutiques contenant du tadalafil
WO2014055047A1 (fr) Combinaison d&#39;un agent actif dérivé de la quinone et d&#39;une cholinestérase
EP3360542A1 (fr) Formes de comprimés de chlorhydrate de vilazodone
WO2014007775A1 (fr) Nouvelle formulation à dissolution rapide
EP3843702B1 (fr) Combinaison à dose fixe et à libération immédiate de mémantine et de donépézil
ES2868602T3 (es) Preparación de compuesto farmacéutico

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13762603

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13762603

Country of ref document: EP

Kind code of ref document: A1